Academic Journals Database
Disseminating quality controlled scientific knowledge

Emerging treatments for essential thrombocythemia

ADD TO MY LIST
 
Author(s): Okoli S | Harrison C

Journal: Journal of Blood Medicine
ISSN 1179-2736

Volume: 2011;
Issue: default;
Start page: 151;
Date: 2011;
Original page

ABSTRACT
Steven Okoli, Claire HarrisonDepartment of Haematology, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, UKAbstract: In 1934, Epstein and Goedel used the term hemorrhagic thrombocythemia to describe a disorder characterized by permanent elevation of a platelet count to more than three times normal, hyperplasia of megakaryocytes, and the tendency for venous thrombosis and spontaneous hemorrhage. Over the last 75 years, and particularly in the past 6 years, major progress has been made in our understanding of essential thrombocythemia (ET) and its pathogenesis with the identification of the highly prevalent JAK-2 V617F and other mutations. Current management of this condition is based upon historical data and with treatments that have not changed significantly for nearly two decades. This study discusses this and recent progress, highlighting exciting new data with old and new drugs, as well as which patients in particular should be evaluated for these new therapies.Keywords: essential thrombocythemia, interferon, JAK inhibitor
Save time & money - Smart Internet Solutions     

Tango Jona
Tangokurs Rapperswil-Jona